Tercica, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of short stature and other endocrine disorders. Its first product, Increlex, a recombinant human insulin-like growth factor-1 (rhIGF-1) is approved for the long-term treatment of growth failure in children with severe Primary IGF-1 deficiency, or Primary IGFD. The company focuses on marketing and selling Increlex for the treatment for severe Primary IGFD, and developing Increlex as a replacement therapy for primary IGF-1 deficiency or Primary IGFD. Tercica has license and collaboration agreement with Genentech, Inc. to develop, manufacture, and...